Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROIDS-Dose: Weight-based vs Standard Dexamethasone in COVID-19
NCT04834375Phase 3Completed
- Sponsor
- Northwell Health
- Start
- Mar 2021
- Primary completion
- Jan 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dexamethasone in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Northwell Health. Primary endpoint: All Cause Mortality at 28 Days. Started Mar 2021; status: completed.
02
Drugs
dexamethasone
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04834375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04834375.